Search

everythinglearnresearchcommunity

for

Search:↓

ISCK03 stops melanin production in human melanoma cells and lightens skin color in mice and guinea pigs.

Baricitinib shows promise for severe alopecia areata but isn't a cure and has side effects.

Continued ritlecitinib treatment can lead to hair regrowth in some patients with alopecia areata who initially don't respond.

Blocking DPP4 can help activate hair growth and improve hair regeneration.

Cancer treatments can cause various eye problems, so eye doctors should know how to diagnose and treat these early.

Tofacitinib helped a woman regrow hair with no major side effects.

A patient with alopecia had hair regrowth with tofacitinib but developed a skin reaction, choosing to continue the treatment despite the side effect.

Tanshinone IIA helps protect skin tissue from low oxygen damage by boosting certain cell markers.

Ruxolitinib effectively regrows hair in most patients with severe hair loss.

WYE-130600 may cause skin thickening and irritation.

JAK inhibitors show promise for treating skin and hair disorders but need more research on long-term safety and effectiveness.

New pyridine compounds effectively inhibit GSK3, a diabetes treatment target.

Baricitinib is effective for severe alopecia areata with manageable side effects, mainly upper respiratory infections.

Ruxolitinib helps protect skin stem cells and keeps skin healthy in mice with skin GVHD.

JAK inhibitors are effective for long-term management of alopecia areata.

Upadacitinib improves life quality for Alopecia Areata patients without worsening skin issues.

Ritlecitinib 50 mg effectively promotes and sustains hair regrowth in alopecia areata patients.

Upadacitinib can effectively regrow hair in alopecia areata patients without worsening sarcoidosis.

Tofacitinib may be safe and effective for treating certain skin conditions in children.

Ritlecitinib is a new treatment for severe hair loss in people 12 and older.

Janus kinase inhibitors may effectively treat severe alopecia areata unresponsive to other treatments.

Ritlecitinib helped most alopecia areata patients regrow hair by Week 48.

Nilotinib may cause gray hair to return to its original color.

Ritlecitinib provides new treatment options for diverse alopecia areata patients.

Tofacitinib is effective and safe for treating severe hair loss in Korean patients.

Upadacitinib improved symptoms and hair regrowth in a teen with multiple autoimmune conditions.

Janus kinase inhibitors may help treat cutaneous T-cell lymphoma, but more research is needed.

A man developed skin issues from cancer medication, which improved with specific treatments.

Aldesleukin can treat certain cancers and increase HIV patient CD4+ counts but often causes severe side effects.